BACKGROUND AND OBJECTIVES: Definitive chemoradiotherapy (CRT) is considered curative intent treatment for locally advanced esophageal squamous cell carcinoma. Data concerning the usefulness of definitive CRT in patients with esophageal adenocarcinoma (ADC) are lacking. The aim of the study was to compare the results of definitive CRT versus surgery in patients with an ADC. METHODS: All consecutive patients with a non-metastatic ADC treated between 1994 and 2008 were retrospectively assessed. Patients were divided into two groups: surgery group (±pre-operative treatment) versus definitive CRT group. RESULTS: In surgery and definitive CRT groups, 67 and 79 patients were evaluated, respectively. A complete resection was achieved in 92.5% of patients in surgery group and a clinical complete response was observed in 49.4% of patients in definitive CRT group. Overall survival was 36.2 ± 2.0 months in surgery group versus 16.5 ± 0.8 months in definitive CRT group (P = 0.02). The predictive factors of survival were age (P < 0.01), stage (P = 0.04), WHO performance status (P < 0.01), initial weight loss (P < 0.01), and the treatment group (P < 0.01). CONCLUSIONS: The results of the study do not support definitive CRT as an alternative to surgery in esophageal ADC treatment. Definitive CRT should be reserved for patients with a major operative risk.
BACKGROUND AND OBJECTIVES: Definitive chemoradiotherapy (CRT) is considered curative intent treatment for locally advanced esophageal squamous cell carcinoma. Data concerning the usefulness of definitive CRT in patients with esophageal adenocarcinoma (ADC) are lacking. The aim of the study was to compare the results of definitive CRT versus surgery in patients with an ADC. METHODS: All consecutive patients with a non-metastatic ADC treated between 1994 and 2008 were retrospectively assessed. Patients were divided into two groups: surgery group (±pre-operative treatment) versus definitive CRT group. RESULTS: In surgery and definitive CRT groups, 67 and 79 patients were evaluated, respectively. A complete resection was achieved in 92.5% of patients in surgery group and a clinical complete response was observed in 49.4% of patients in definitive CRT group. Overall survival was 36.2 ± 2.0 months in surgery group versus 16.5 ± 0.8 months in definitive CRT group (P = 0.02). The predictive factors of survival were age (P < 0.01), stage (P = 0.04), WHO performance status (P < 0.01), initial weight loss (P < 0.01), and the treatment group (P < 0.01). CONCLUSIONS: The results of the study do not support definitive CRT as an alternative to surgery in esophageal ADC treatment. Definitive CRT should be reserved for patients with a major operative risk.
Authors: Haris Zahoor; James D Luketich; Ryan M Levy; Omar Awais; Daniel G Winger; Michael K Gibson; Katie S Nason Journal: J Thorac Cardiovasc Surg Date: 2014-10-14 Impact factor: 5.209
Authors: Caitlin C Murphy; Arlene M Correa; Jaffer A Ajani; Ritsuko U Komaki; James W Welsh; Stephen G Swisher; Wayne L Hofstetter Journal: J Gastrointest Surg Date: 2013-05-29 Impact factor: 3.452
Authors: Z Faiz; M van Putten; R H A Verhoeven; J W van Sandick; G A P Nieuwenhuijzen; M J C van der Sangen; V E P P Lemmens; B P L Wijnhoven; J T M Plukker Journal: Ann Surg Oncol Date: 2019-02-04 Impact factor: 5.344
Authors: Brett S Walker; Thomas L Sutton; Luai Zarour; John G Hunter; Stephanie G Wood; V Liana Tsikitis; Daniel O Herzig; Charles D Lopez; Emerson Y Chen; Skye C Mayo; Melissa H Wong Journal: Ann Surg Oncol Date: 2021-08-07 Impact factor: 5.344